Meeting Banner
Abstract #2335

Early non-invasive prediction of response to Temozolomide in low-grade glioma

Marina Radoul1, Elavarasan Subramani1, Chloe Najac1, Georgios Batsios1, Anne Marie Gillespie1, and Sabrina Ronen1

1Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States

Newly diagnosed low-grade glioma (LGG) patients have a relatively long survival, but nonetheless ultimately recur. New therapies are therefore being considered for LGG. One approach is the use of Temozolomide, previously reserved for treating high grade glioblastoma. However, early indicators of response are still needed. Here, we investigated response to Temozolomide treatment in an orthotopic LGG mouse model. Using 1H MRS we detected an early decrease in total choline and a surprising increase in both glutamine and glutamine plus glutamate that were associated with ultimate tumor shrinkage. This identifies potential early metabolic biomarkers of response to Temozolomide treatment in LGG.

This abstract and the presentation materials are available to members only; a login is required.

Join Here